Dabur India Ltd Q4 FY2023 Concall Summary

Key Takeaways

• A year of margin pain, ending with a volume miss: Consolidated gross margins contracted 258 bps for FY23, and Q4 volume was nearly flat as unseasonal rains wiped out seasonal primary loading, despite secondary growth holding at ~10%.
• Portfolio diversification is the hedge, not the driver: The low-margin Foods & Beverage business surged while high-margin Healthcare cycled a COVID base, creating a mix headwind that masked market share gains in Hair Oils, Oral Care, and Home Care.
• Rural stress is structural and persistent: Down-trading to smaller packs and sachets is widening the gap between case growth and volume growth, and management sees no quick fix, echoing distress signals from auto and other sectors.
• A new allopathic push in Healthcare is the boldest strategic bet: A dedicated 440-person team under a new ex-Himalaya CEO will target 15-16 lakh allopathic doctors, aiming for ₹200 cr from the new Therapeutics division.
• What to watch next quarter: Whether the promised gross margin inch-up materializes as input inflation cools, whether rural green shoots translate to volume, and how quickly the Healthcare base normalizes.

Margin Structure & Cost Pressures

• Gross margin hit was a mix story, not just inflation: On a pure cost-to-cost basis, 6% input inflation was fully offset by 6% price increases in India. The 75 bps India gross margin contraction split roughly evenly between adverse product mix (35-40 bps) and higher consumer promotions and trade interventions (35-40 bps).
• International margins suffered from country mix: MENA saliency reduced because of a distribution rearrangement that caused a ~10% decline there, while other markets with currency depreciation shot up, pressuring translated INR growth and margins.
• Other expenses jumped on volume mix, not leakage: 60% of other expenses are variable and grew in line with ~11% case sale growth, driven by freight (high-tonnage Food season) and one-offs: ~₹20 cr adverse Forex from Sri Lanka, ~₹10 cr CSR phasing, and MENA distribution restructuring costs. No Badshah-related expense sat in the base.
• Case growth is structurally outpacing volume growth: Rural down-trading to low unit price points means case growth runs ahead of volume growth, and management confirmed this means other expense growth will stay ahead of sales growth until rural recovers.
• The margin recovery promise is cautious and conditional: Management will not commit to a 20% operating margin timeline, prioritizing media reinvestment first; the near-term target is only ~19-19.5%, with gross margin expansion expected as rural recovers and petroleum-based input prices soften.

Mohit Malhotra: "I can't say with confidence that we'll inch up to a level of 20% in 1 year or will it take us 2 years, because our media spending has also gone down. And whatever upside that we get in gross margin, we want to invest in media, and we want to put it in operating margin."

Category & Brand Performance

• Primary-secondary gap was weather, not destocking: Unseasonal rains in March-April in North India prevented end-of-quarter seasonal loading for Beverages, Healthcare (Pudin Hara, glucose), and Hair Oil; secondary growth remained intact at ~10%, and no pipeline correction is intended.
• NPD strategy is weed-and-feed: ~180 SKUs culled in the last 6 months (sanitizers, Tulsi Drops, Haldi Drops failed), while successful extensions like Pudin Hara fizz, Shilajit gel, and Oral Care gel (now ₹20 cr) are scaling nationally.

Mohit Malhotra: "It will be a weed and feed strategy. You keep weeding out SKUs which are not doing well, but you keep feeding within the guardrails of your core business, which is it will be Real, it will be Amla, it will be Red."

Healthcare Restructuring

• New vertical and leadership: Ex-Himalaya CEO Mr. Philipe Haydon has joined to head the restructured Healthcare business, which now has three verticals (Health Supplement, OTC, Ethical) plus a fourth, Dabur Therapeutics Limited, manned by ~440 people.
• Allopathic doctor advocacy is the big pivot: A dedicated team will now cover 15-16 lakh allopathic doctors in key metros, a departure from the historical approach of primarily visiting ayurvedic doctors. The Therapeutics division has been given a target of roughly ₹200 cr.
• Baby Care is being built on the same advocacy model: Targeting ₹20 cr scaling to ₹40-50 cr next year, driven by advocacy to gynecologists and pediatricians.
• Healthcare growth expectation is modest: Management expects high single-digit to low double-digit growth going forward, with the negative base effect now out of the way.

Mohit Malhotra: "Unlike hitherto we were only going to ayurvedic doctors, now we are going to allopathic doctors. There are almost like around 15 to 16 lakh allopathic doctors. So, in the key metros, we'll be reaching out to those doctors doing advocacy and they have been given a target of roughly around Rs. 200 crores."

Foods & Beverages: The Growth Engine

• Badshah acquisition integrated cautiously: Consolidated for the first time in Q4; focus is on Gujarat, Maharashtra, and Andhra Pradesh, with national expansion gated behind advertising to create pent-up demand first. Spices inflation of ~20% is pressuring gross margins, met with price increases, pack architecture changes, and grammage reductions.
• Separate beverage distribution network being carved out: A dedicated distribution network for juices, nectars, and drinks is being built, separate from Healthcare and grocery distribution, targeting E&D (eating and drinking) outlets with separate credit extension and stockist investment.
• Ambitious scale targets: The ₹1,700 cr Food & Beverage vertical is targeted to double to ₹4,000-5,000 cr in 5 years (18-19% CAGR); the drinks business (Real Koolerz) alone is targeted to go from ₹200 cr to ₹500 cr in 5 years.
• Growth is moderating from peak: Foods growth will settle to high single-digit to low double-digit from the ~30% pace, as 90% of the portfolio is the high-base ₹1,700 cr Tetra Pak business.

Mohit Malhotra: "We don't want to put pressure on Badshah to extend to all India at the moment until and unless we start the national advertising there and create some sort of pent-up demand before we start distribution there. We don't want the stocks to get stuck anywhere."

Rural Demand & Distribution

• Rural distress is deep and broad: Recovery of payments is not happening at super-stockist, sub-stockist, or retail level, so stockists are not selling out in rural areas. Down-trading is significant: consumers buying 50 mL instead of 100 mL, sachet sales picking up.
• Management sees no contradiction with other sectors: When asked about the disconnect with tractor sales growing 15% and microfinance doing well, management acknowledged having no exact answer and said rural stress has been echoed by other industries, including Maruti, at Board meetings.
• Central region is reviving, South is under pressure: UP and Bihar (Central region) saw 7% secondary growth after leadership and manpower changes post-elections; South is being corrected; West and East are doing well.
• Green shoots are tentative: Early signs of rural demand revival emerged toward the end of Q4, but the divergence between case growth and volume growth may persist as long as rural lags urban.

Mohit Malhotra: "Exact answer, I really don't have, if other companies and other industries are doing well in rural and we are not. But that's not what we hear. I think rural stress has actually been echoed by most of the companies at our Board meetings also, where people are representing different industries, be it Maruti or others."

Guidance & Commitments

Key Metrics